A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
This protocol describes a novel and efficient method to quickly initiate operant responding for ethanol in rats that, contrary to standard methods, does not require water deprivation or saccharin/sucrose fading to initiate responding.
Operant oral self-administration methods are commonly used to study the reinforcing properties of ethanol in animals. However, the standard methods require saccharin/sucrose fading, water deprivation and/or extended training to initiate operant responding in rats. This paper describes a novel and efficient method to quickly initiate operant responding for ethanol that is convenient for experimenters and does not require water deprivation or saccharin/sucrose fading, thus eliminating the potential confound of using sweeteners in ethanol operant self-administration studies. With this method, Wistar rats typically acquire and maintain self-administration of a 20% ethanol solution in less than two weeks of training. Furthermore, blood ethanol concentrations and rewards are positively correlated for a 30 min self-administration session. Moreover, naltrexone, an FDA-approved medication for alcohol dependence that has been shown to suppress ethanol self-administration in rodents, dose-dependently decreases alcohol intake and motivation to consume alcohol for rats self-administering 20% ethanol, thus validating the use of this new method to study the reinforcing properties of alcohol in rats.
The development of animal models to study the reinforcing effects of drugs has proven an important tool to study human drug addiction. More specifically, operant self-administration is a widely used behavioral model that is one of the most effective means for assessing the positive reinforcing effects of an orally consumed ethanol solution. An early issue with developing such a model was the primary aversive taste of high concentrations of ethanol for most rodents, a phenomenon that is also shared in humans with little or no experience with alcohol1. A standard protocol to overcome this barrier requires water deprivation and/or saccharin or sucrose fading for the acquisition and maintenance of self-administration. However, these two approaches are not advantageous. They require long periods of training to simply initiate responding for ethanol and obtain a relative success rate of acquisition. The use of sweeteners also introduces a potential bias in the interpretation of the self-administration data. These limitations don't apply to the following protocol.
Briefly, Samson and colleagues2 have shown that dissolving ethanol in a sweet solution of 20% sucrose and then fading out the sweetness over 4 weeks of training is required to initiate responding for 10% ethanol in water. Furthermore, reliable ethanol intake is usually achieved in 6 to 8 weeks1-3. This approach is highly problematic. First, it requires extended periods of training before investigators can begin to measure ethanol self-administration. In contrast, intravenous self-administration of cocaine or heroin requires 0 - 1 days of pre-drug training on a food-delivering lever in food restricted animals, and stable responding for drug is often achieved in 10 - 12 days4,5. Another limitation of this method is the fact that saccharin and sucrose are highly rewarding to rats and elicit brain activation patterns similar to drugs of abuse, thus introducing the potential for confounds in ethanol self-administration studies6-9. Finally, rats acquiring self-administration of an ethanol solution using this method show variability in acquisition and response rate1,10, with a substantial proportion of rats consistently excluded from experiments due to unsuccessful acquisition and/or insufficient response rate.
By contrast, with this protocol, we present a simple yet efficient method for acquisition and maintenance of oral self-administration of a 20% ethanol in water solution that does not necessitate water deprivation, sucrose/saccharin fading or extended access training. A recent investigation found that self-administration for oral ethanol displays an inverted U shaped dose response curve with highest ethanol intake during self-administration at a 20% ethanol concentration, thus providing a rationale for selecting 20% ethanol solution in our experimental design11.
All procedures are conducted in accordance with the NIH Guide for Care and Use of Laboratory Animals.
1. Animal Care and Housing
2. Operant Training
3. Testing the Predictive Validity of an Operant Model of Alcohol Self-administration
Note: Once rats have acquired a stable self-administration baseline (see step 2), it is possible to assess the predictive validity of the model by testing the efficacy of naltrexone, a currently FDA-approved medication for alcohol dependence in reducing 20% ethanol self-administration. We recommend doing this testing on the highest FR achieved during training (FR2), when responses are reliably high. Once predictive validity is established, the model can be used to evaluate new drug candidates.
Figure 1 shows the representative self-administration behavior of operant- and drug-naive Wistar rats (eight different cohorts amounting to a total of 239 rats) trained on a FR1 schedule to self-administer 20% ethanol without water deprivation or saccharin/sucrose fading during 30-minute sessions. With this protocol, rats initiate lever pressing to obtain an ethanol reward very quickly, already obtaining more than 10 rewards during the first sessions (Figure 1A
With this protocol, we are presenting a new method to acquire and maintain stable oral self-administration of 20% ethanol in rats that, contrary to classic models of ethanol self-administration, does not require the use of water deprivation, extended access training, or saccharin/sucrose fading12. Furthermore, naltrexone, a currently FDA-approved medication for alcohol dependence, successfully decreases alcohol self-administration and the motivation to consume alcohol of Wistar rats trained with this protocol....
The authors have nothing to disclose.
This work was supported by the Swedish Research Council.
Name | Company | Catalog Number | Comments |
Extra Tall MDF Sound Attenuating Cubicle, Interior: 22"W x 22"H x 16"D | Med Associates Inc. | ENV-018MD | |
Extra Tall Modular Test Chamber with modified Top, Waste Pan and Photobeam | Med Associates Inc. | ENV-007CT-PH | |
Stainless Steel Grid Floor for Rat or Small Primate | Med Associates Inc. | ENV-005 | |
Retractable Lever | Med Associates Inc. | ENV-112CM | 2 by SA chambers |
Stimulus Light, 1" White Lens, Mounted on Modular Panel | Med Associates Inc. | ENV-221M | 2 by SA chambers |
Dual Cup Liquid Receptacle with 18 ga Stainless Steel Pipes | Med Associates Inc. | ENV-200R3AM | |
Single Speed Syringe Pump, 3.33 rpm | Med Associates Inc. | PHM-100 | |
Liquid Delivery Kit | Med Associates Inc. | PHM-122-18 | |
SmartCtrl 8 Input / 16 Output Package | Med Associates Inc. | DIG-716P2 | |
MED-PC software | Med Associates Inc. | SOF-735 | |
http://www.mednr.com/ | Med Associates Inc. | A website that is open-source and has been created to offer researchers a place to exchange MEDState Notation code | |
Kendall Monoject 20 cc Syringes, Regular Luer Tip | VWR International | MJ8881-520657 | |
Ethanol, Pure, 190 Proof (95%), USP, KOPTEC | Decon Labs | 2801 | |
0.9% Sodium Chloride Injection, USP | Hospira | 0409-4888-50 | |
Naltrexone hydrochloride | Sigma Aldrich | N3136-1G | |
23 G BD PrecisionGlide Needles | BD | 305145 | |
Minivette POCT 50 µL, K3EDTA | Sarstedt | 17.2113.150 | For capillary blood collection |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved